NASDAQ : ACHV
Achieve Life Sciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.83 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 702.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 702.82M |
| Enterprise Value | 530.47M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 102.90M |
| Shares Outstanding | 102.90M |
| Shares Change (YoY) | +82.32% |
| Shares Change (QoQ) | +75.17% |
| Owned by Insiders (%) | 2.31% |
| Owned by Institutions (%) | 60.24% |
| Float | 74.69M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 100.80 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.95 |
| Quick Ratio | 0.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.63 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -844.99% |
| Return on Assets (ROA) | -29.21% |
| Return on Invested Capital (ROIC) | -140.36% |
| Return on Capital Employed (ROCE) | 807.40% |
| Weighted Average Cost of Capital (WACC) | 16.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.07M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.31 |
| 52-Week Price Change | +37.98% |
| 50-Day Moving Average | 7.45 |
| 200-Day Moving Average | 5.64 |
| Relative Strength Index (RSI) | 46.41 |
| Average Volume (20 Days) | 1,308,690 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17.81M |
| Short Previous Month | 17.47M |
| Short % of Shares Out | 17.30% |
| Short % of Float | 23.84% |
| Short Ratio (days to cover) | 12.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -58.28M |
| Pretax Income | -114.04M |
| Net Income | -114.04M |
| EBITDA | -58.05M |
| EBIT | -58.28M |
| Earnings Per Share (EPS) | -$1.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 187.30M |
| Total Debt | 14.95M |
| Net Cash | 172.36M |
| Net Cash Per Share | $1.67 |
| Equity (Book Value) | -14.68M |
| Book Value Per Share | -0.14 |
| Working Capital | -9.36M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -47.02M |
| Capital Expenditures | -19,000 |
| Depreciation & Amortization | 225,000 |
| Net Borrowing | 5.00M |
| Free Cash Flow | -47.04M |
| FCF Per Share | -$0.46 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -82.32% |
| Shareholder Yield | -82.32% |
| Earnings Yield | -26.49% |
| FCF Yield | -6.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.15 |
| Price Target Difference | 107.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 31, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |